A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing, Multiple Ascending Dosing and Food-effect in Healthy Volunteers

Trial Profile

A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing, Multiple Ascending Dosing and Food-effect in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2015

At a glance

  • Drugs ALS 8176 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man
  • Sponsors Alios BioPharma
  • Most Recent Events

    • 13 Jan 2014 Top-line results in 100 subjects reported in an Alios BioPharma media release.
    • 13 Jan 2014 Status changed from recruiting to completed, according to an Alios BioPharma media release.
    • 29 Jul 2013 New source identified and integrated: ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top